InnoCare Pharma Limited (09969) submitted its Monthly Return for 30 November 2025, showing that its authorized share capital remains unchanged at USD50,000, with a par value of USD0.000002 per share.

As of the close of November, the company’s total number of issued ordinary shares listed on The Stock Exchange of Hong Kong Limited stood at 1,493,798,235, alongside 2,486,000 treasury shares, leading to a combined total of 1,496,284,235. Trading in the company’s Shanghai-listed shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange remained at 268,359,717 shares, with no changes during the month.

No new shares were issued or transferred out of treasury under the 2023 and 2024 RMB Share Incentive Schemes. Both schemes showed no increase in total issued shares, though a certain number of Restricted Shares could be granted in future as per the approved share incentive outlines. In the absence of any movement in warrants, convertibles, or share repurchases, the total share capital and treasury share count remained steady through November.